Artiva Biotherapeutics, Inc.
ARTVNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $0 | $251,000 | $32.9M |
| Operating income | −$89.8M | −$67.3M | −$30.7M |
| Net income | −$83.9M | −$65.4M | −$28.7M |
| Total assets | $130.9M | $209.6M | $105.1M |
| Total liabilities | $21.0M | $22.9M | $50.7M |
| Equity | $110.0M | $186.6M | −$162.0M |
| EPS (diluted) | $-3.43 | $-5.81 | $-35.78 |
| Shares out. | 24.4M | 11.3M | 802,747 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −76.3%
- Return on assets
- −64.0%
- Return on capital (ROCE)
- −76.2%
- Liabilities / assets
- 16.0%
- Debt / equity
- 0.19×
- Book value / share
- $4.51
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -2.34distress
- Accruals / assets
- −5.4%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2027-08AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- Phase 2Recruitingreadout ~2028-01AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Gc Corp.Activist (13D)May 28, 2026
- Viking Global Investors LpPassive (13G)May 18, 2026
- Ra Capital Management, L.P.Activist (13D)May 13, 2026
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Venbio Global Strategic Fund Iii, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Gc Corp.10% owner | May 11, 2026 | Buy | 1.1M | $11.52 |
| Raymon HeatherOfficer — SVP, Research and Development | May 19, 2026 | Sell | 3,095 | $9.01 |
| Horan ChristopherOfficer — Chief Tech Operations Officer | May 19, 2026 | Sell | 7,002 | $9.01 |
| Bush JenniferOfficer — COO, CLO, Compliance Officer | May 19, 2026 | Sell | 8,790 | $9.01 |
| Banerjee SubhashisOfficer — Chief Medical Officer | May 19, 2026 | Sell | 7,037 | $9.01 |
| Aslan FredOfficer — Chief Executive Officer | May 19, 2026 | Sell | 27,116 | $9.01 |
| Miralles Gines DiegoOfficer — President & Head of R&D | May 18, 2026 | Grant | 77,500 | $0.00 |
| Ra Capital Management, L.P.Director | May 11, 2026 | Buy | 6.5M | $11.52 |
| Huston Thad AllenOfficer — Chief Financial Officer | Mar 10, 2026 | Grant | 220,000 | $0.00 |
| Raymon HeatherOfficer — SVP, Research and Development | Feb 15, 2026 | Grant | 46,000 | $0.00 |
| Horan ChristopherOfficer — Chief Tech Operations Officer | Feb 15, 2026 | Grant | 117,300 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 480,579 | 1.0 | +109.1% |
| Apr 30, 2026 | 229,817 | 1.0 | +54.8% |
| Apr 15, 2026 | 148,487 | 1.0 | +0.2% |
| Mar 31, 2026 | 148,199 | 1.2 | +0.7% |
| Mar 13, 2026 | 147,133 | 1.0 | -1.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 19, 2026
- Other material eventMay 8, 2026
- Results of operations · Regulation FD disclosure · Other material eventMay 8, 2026
- Results of operationsMar 10, 2026
- Director / officer changeFeb 24, 2026
- Director / officer changeFeb 19, 2026
- Director / officer changeDec 12, 2025
- Regulation FD disclosure · Other material eventNov 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.